Objectives: In order to avoid separate injections, admixtures of drugs are frequently used in palliative care settings. There are different factors that can influence the compatibility and stability of the mixture: drug type, concentration, solvent, container, temperature and light. There are some mixtures of drugs with proven stability, but there is lack of evidence about the stability and compatibility of the combination of morphine and furosemide. The purpose is to evaluate the compatibility and stability of two admixtures of morphine and furosemide at two different temperatures (25ºC and 37ºC). The concentrations of the admixtures are: 3.0 mg/mL-2.0 mg/mL; 1.0 mg/mL-0.6 mg/mL; in NaCl 0.9% stored in elastomeric infusors protected from light. Methods: The samples were prepared and diluted in NaCl 0.9% in elastomeric infusor in triplicate to obtain four different conditions of concentration and/or temperature of storage (concentration: 3.0 mg/mL-2.0 mg/mL, 1.0 mg/mL-0.6 mg/mL of morphine and furosemide respectively; temperature of storage 25ºC and 37ºC). The concentration of each constituent drug into different mixtures was periodically determined using a HPLC-UV method. The drugs were chromatographed on a C 18 reverse phase column; the mobile phase was acetonitrile-water 40:60 (v/v); flow rate 1.5 mL/min. Morphine and furosemide concentrations were determined at 235 nm by interpolation from the calibration curves prepared at (0, 1, 2, 3, 7, 8, 9, 10, 14, 15) days from the standards. Statgraphics centurion XVI program has been used to data treatment. Results: The stability of the admixtures diluted in NaCl 0.9% are as follow: morphine-furosemide (3.0 mg/mL-2.0 mg/mL) is stable (retained > 95% of their initial concentration) eight days at 25ºC and two day at 37ºC; (1.0 mg/mL-0.6 mg/mL) is stable thirty days at 25ºC and two day at 37ºC. Conclusion: The admixture of morphine and furosemide in NaCl 0.9% in elastomeric infusor can be safely used in palliative care for at least two days. Concentrations of the admixture can be prepared in advance and stored at room temperature, but the infusion cannot be longer than two days.
INTRODUCTION
The definition of the World Health Organization (WHO)
1 about palliative care is follow: an approach that improves the quality of life of patients and their families facing the problem associated with life-threatening illness, through the prevention and relief of suffering by means of early identification and impeccable assessment and treatment of pain and other problems, physical, psychosocial and spiritual. Palliative care provides relief from pain and other distressing symptoms affirms life and regards dying as a normal process, intends neither to hasten or postpone death, integrates the psychological and spiritual aspects of patient care, offers a support system to help patients live as actively as possible until death, offers a support system to help the family cope during the patients illness and in their own bereavement, uses a team approach to address the needs of patients and their families, including bereavement counselling, if indicated, will enhance quality of life, and may also positively influence the course of illness, is applicable early in the course of illness, in conjunction with other therapies that are intended to prolong life, such as chemotherapy or radiation therapy, and includes those investigations needed to better understand and manage distressing clinical complications.
To obtain optimal symptom control in these patients, the simultaneous administration of more than one drug is often required.
2
When the oral administration of drugs is no longer possible at a later stage of the disease because symptoms worsen and the patient's general condition deteriorates, alternative methods of delivering the drugs may be necessary. The ideal system should deliver the drug reliably in a pain-free manner, use a minimum amount of nursing time and allow the patient remain mobile. In addition, it should be simple to use and not too costly.
3
To avoid the use of different infusion needles, it may be beneficial to mix different drugs in one single infuser. Drug infusers offer the possibility of continuous subcutaneous drug administration that, compared to intermittent injections, gives a more constant plasma concentration. The continuous subcutaneous infusion of drugs has become an accepted practice, especially in the palliative care of cancer patients, in the 20 years.
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The patients tolerate the treatment well, and infusionsite infection and abscess are rare.
Morphine is an opioid analgesic used for the treatment of moderate to severe pain. It is recommended by the WHO for the relief of moderate cancer-related pain. It is the opioid of choice in palliative and terminal care. Morphine is predominantly cleared from body by metabolism to morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G). Furosemide is a loop diuretic, which is an anthranilic acid derivative
Graphical abstract benzoic acid) used in the treatment of congestive heart failure and edema. His medication is also used to treat high blood pressure (hypertension). Furosemide works by blocking the absorption of salt and fluid in the kidney tubules, causing a profound increase in urine output (diuresis). The diuretic effect of furosemide can cause body water and electrolyte depletion. Therefore, careful medical supervision is necessary during treatment.
The physical compatibility and/or stability of several drugs in solution destined to subcutaneous infusion has been widely studied, [7] [8] [9] [10] [11] although in some studies only visual inspection of the samples was performed, providing information on the physical compatibility but not on the chemical stability of the drugs in the mixture. Moreover, studies have not yet been done regarding the combination of morphine and furosemide in solution in which the quantification of both drugs was performed by HPLC. On the other hand, patients will only benefit from the use of mixtures if those mixtures are of good quality since the administration of incompatible mixtures could cause irritation. Besides, chemical incompatibility and instability of the drugs in the mixture will result in an inadequate therapeutic outcome, and the degradation products may cause additional side effects.
Therefore, the aim of this study was to determine the compatibility and stability of morphine and furosemide combined in solution at two different concentrations and stored in elastomeric infusors protected from light at 25ºC and 37ºC over a period of 15 days.
MATERIAL AND METHODS

Materials
Commercial morphine ampoules of 20 mg/mL (Morphine, Braun, Spain) and commercial furosemide ampoules of 20 mg/2 mL (Furosemide, Fresenius Kabi, Spain) were used. Sodium chloride 0.9% was obtained from Fresenius Kabi, Spain. HPLC-grade acetonitrile was obtained from Sigma-Aldrich. Other chemical and solvents were of analytical grade and obtained from Sigma-Aldrich, Germany. High purity water (resistivity 18.2 MΩ cm) obtained by a Milli-Q water purification system (Millipore, Bedford, MA, USA) was used throughout this work.
Drug mixtures
The doses of morphine and furosemide assayed in the study were chosen taking into consideration those more frequently used by the units of palliative care in our region. The doses assayed were 3.0 mg/mL-2.0 mg/mL and 1.0 mg/mL-0.6 mg/mL of morphine and furosemide respectively, which were prepared in 0.9% normal saline for injection and stored at two temperatures, 25°C and 37ºC each one, employing a bacteriological and culture oven with temperature and time regulation and digital reading, Selecta (INCUDIGIT 19L 2001246) . Each of these four alternatives were prepared in triplicate in elastomeric infuser and protected from light and also in glass. From each mixture, five standards of different concentrations between 25 mg/mL and 160 mg/mL of admixture were prepared. The standards were divided into different aliquot parts, stored in eppendorf tubes and frozen until each analysis day. All the procedures were done under aseptic conditions and using sterile drug solutions.
Physical stability study
The physical stability of the samples was assessed by visual examination during all studied days for colour change and/or precipitation.
Chemical stability study
Mixtures concentrations were determined by a stability-indicating HPLC method. HPLC analysis was performed at room temperature (~25ºC) using a Shimadzu LC-6A pump equipped with Rheodine 7125 injection valve 20 μL, a Shimadzu SPD-6A spectrophotometric detector working at 235 nm. The signal from the detector was recorder and integrated with a chromatography data system Shimadzu C-R6A chromatopac; a LiChrospher® 100 C18 (5 μm) LiChroCART® 250-4 column was employed. The mobile phase consisted of acetonitrile: water (40:60, v/v) delivered at flow rate of 1.0 mL/ min. The sample injection volume was 20 μL, and triplicate injections were performed for every sample. The initial concentration of mixture was defined as 100%, and subsequent sample concentrations were expressed as a percentage of the initial concentration. Stability of the mixture was defined as retention of at least 95% of the initial mixture concentration.
Forced degradation analysis
Forced degradation is a degradation of new drug substance and drug product at conditions more severe than accelerated conditions. It is required to demonstrate specificity of stability indicating methods and also provides an insight into degradation path ways and degradation products of the drug substance.
12-13
In this work, six different studies were carried out for this purpose over the mixture solution: acid, base, heat, UV light, hydrogen peroxide and sodium hypochlorite.
Compatibility and stability studies
The compatibility and stability studies were performed at 25 ± 0.5ºC and 37 ± 0.5ºC, and all drug mixtures were protected from direct light exposure. All solutions were assayed in triplicate with four replicates in each case. At pre-determined times-that is 0, 1, 2, 3, 7, 8, 9, 10, 14, 15 days-the samples were examined for any development and/or change in colour. Also, the drug mixtures were examined for signs of precipitation or cloudiness (turbidity) and gas production under bright light against a dark background.
RESULTS AND DISCUSSION
Accelerated degradation study
The subsequent studies were made over mixture solutions containing 40 mg/L of morphine and 24 mg/L of furosemide.
pH study
To aliquots of 500 μL of mixture were added different amounts of HCl or NaOH (0.1 M and 1 M) (100, 200, 300, 500 of both concentration).Additions of HCl or NaOH have not influence about the chromatographic signal. The area diminishes by effect dilution when the amount of degradant is higher and also the signal is constant with the time. 3.0 mg/mL-2.0 mg/mL 8 2
1.0 mg/mL-0.6 mg/mL 30 2
Heat study
Three samples of mixture solutions were heated at different temperatures (40ºC, 60ºC, 80ºC) during different times (from 5 to 60 minutes). No significant changes were observed in the chromatograms in all cases.
UV light
A mixture solution was subject to UV irradiation during several days. After one day under UV radiation, the signal of the admixture diminishes and also colour change is observed into glass.
Oxidants
To aliquots of 500 μl of mixture were added different amounts of NaClO 0.2 M and 2 M or H 2 O 2 0.03%, 0.3 and 3% (100, 200, 300, 500 μl of each reagent and concentration). No effects were observed when the concentration of reagents were lower. The chromatographic signal increases and also stays constant with the time when 0.3% and 3% ofH 2 O 2 were used.
Physical stability study
All solutions were initially clear and colourless and remained so for the duration of the study. Visible particles appear into the infusers at the same time decreased the concentration of the admixture stored into they.
Statistical evaluation of data
Calibration curves were linear over the concentration range used with good correlation coefficients. Statistical evaluations of data for different stability studies are presented in Table 1 for each mixture. 
CONCLUSION
This study was proven to be suitable for determining the stability and compatibility of morphine and furosemide mixtures in elastomeric infusors. It may be applied to stablish the stability of different samples prepared in NaCl 0.9 % and stored at two temperatures and can be used in palliative care (Table 4) . It can be prepared in advance and stored at room temperature for at least 8 days, but the infusion with a system worn close to a patient that may reach a temperature closer to 37ºC cannot be longer than two days for both concentrations.
SUMMARY
• Mixture of Morphine-Furosemide (3.0 mg/mL-2.0 mg/mL) is stable eight days at 25ºC and two day at 37ºC
• Mixture of Morphine-Furosemide (1.0 mg/mL-0.6 mg/mL) is stable thirty days at 25ºC and two day at 37ºC
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